These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12901556)

  • 1. DNA-based vaccines for allergic disease.
    Spiegelberg HL; Takabayashi K; Beck L; Raz E
    Expert Rev Vaccines; 2002 Aug; 1(2):169-77. PubMed ID: 12901556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-based approaches to the treatment of allergies.
    Spiegelberg HL; Raz E
    Curr Opin Mol Ther; 2002 Feb; 4(1):64-71. PubMed ID: 11883696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy.
    Spiegelberg HL; Horner AA; Takabayashi K; Raz E
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):547-51. PubMed ID: 14752340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccines for the prevention and treatment of allergy.
    Chua KY; Kuo IC; Huang CH
    Curr Opin Allergy Clin Immunol; 2009 Feb; 9(1):50-4. PubMed ID: 19532092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
    Linhart B; Hartl A; Jahn-Schmid B; Verdino P; Keller W; Krauth MT; Valent P; Horak F; Wiedermann U; Thalhamer J; Ebner C; Kraft D; Valenta R
    J Allergy Clin Immunol; 2005 May; 115(5):1010-6. PubMed ID: 15867859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DNA vaccines against allergy].
    Sato Y; Kasukawa R
    Nihon Rinsho; 2000 Jun; 58(6):1307-14. PubMed ID: 10879058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for the development of safe and effective DNA vaccines for allergy treatment.
    Hartl A; Weiss R; Hochreiter R; Scheiblhofer S; Bauer R; Valenta R; Ferreira F; Leitner W; Thalhamer J
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):279-98; discussion 299. PubMed ID: 15119049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.
    Creticos PS; Lichtenstein LM
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):304-12; discussion 312-3. PubMed ID: 15119051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel vaccines and adjuvants for allergen-specific immunotherapy.
    Crameri R; Rhyner C
    Curr Opin Immunol; 2006 Dec; 18(6):761-8. PubMed ID: 17010585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines for allergy treatment.
    Weiss R; Scheiblhofer S; Thalhamer J
    Methods Mol Med; 2006; 127():253-67. PubMed ID: 16988459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines for allergy treatment.
    Hartl A; Weiss R; Hochreiter R; Scheiblhofer S; Thalhamer J
    Methods; 2004 Mar; 32(3):328-39. PubMed ID: 14962768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S; Deifl S; Bohle B
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine encoding Der p 2 allergen generates immunologic protection in recombinant Der p 2 allergen-induced allergic airway inflammation mice model.
    Li GP; Liu ZG; Qiu J; Ran PX; Zhong NS
    Chin Med J (Engl); 2005 Apr; 118(7):534-40. PubMed ID: 15820083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
    Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune mechanisms of allergen-specific sublingual immunotherapy.
    Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L
    Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotechnology-based allergy diagnosis and vaccination.
    Bhalla PL; Singh MB
    Trends Biotechnol; 2008 Mar; 26(3):153-61. PubMed ID: 18222557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergen immunotherapy: novel approaches in the management of allergic diseases and asthma.
    Campbell D; DeKruyff RH; Umetsu DT
    Clin Immunol; 2000 Dec; 97(3):193-202. PubMed ID: 11112358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.